Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment

Exclusion Criteria

• •Subjects will be excluded if they meet any of the following criteria:
• •1. Total occlusion (TIMI 0 flow) lesion;
• •2. In-stent restenosis lesion;
• •3. Concurrent left main disease or severe three-vessel disease requiring coronary artery bypass grafting;
• •4. Target lesion with severe calcification or tortuosity that cannot be crossed by guidewire;
• •5. Coronary artery bypass graft stenosis;
• •6. Confirmed ST-elevation myocardial infarction;
• •7. Cardiogenic shock or requiring mechanical respiratory and circulatory support;
• •8. Hemodynamically unstable tachyarrhythmia or bradyarrhythmia;
• •9. Severe renal insufficiency or undergoing hemodialysis;
• •10. Known allergy or intolerance to aspirin, clopidogrel, ticagrelor, heparin, contrast media, paclitaxel, sirolimus and/or other analogues;
• •11. Systemic lupus erythematosus or other systemic autoimmune diseases;
• •12. History of stroke within 6 months prior to enrollment;
• •13. Scheduled elective surgery within 6 months after enrollment requiring discontinuation of anticoagulant or antiplatelet medications;
• •14. Currently participating in other drug or interventional medical device clinical studies;
• •15. Other conditions deemed unsuitable for enrollment by the investigator.